global
Variables
Utilities
CUSTOM STYLES

FDA Approves New Administration Method for Tecentriq (atezolizumab)

September 16, 2024

On September 12, 2024, the U.S. Food and Drug Administration (FDA) announced its approval of Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) for subcutaneous injection, commonly known as a shot. This approval included all the same uses of Tecentriq (atezolizumab) that the FDA previously approved for adults, including treatments for both non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). This latest approval is based on the results of the IMscin001 study, which compared the use of Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) given by a shot (injection) under the skin in the thigh versus Tecentriq (atezolizumab) which is an infusion into the bloodstream (intravenous/IV). People given Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as a shot received the drug over approximately 7 minutes compared to the standard 30-60 minutes when Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) is given by IV. The study showed no difference in the drug’s safety or efficacy between the two administration methods. The follow-up IMscin002 study also showed that 71% of participants preferred the shot over IV injection.Tecentriq (atezolizumab) is a medication previously approved for use in adults for several indications, including NSCLC and SCLC. Adding Hybreza (hyaluronidase-tqjs) to the shot helps improve the absorption and dispersion of Tecentriq (atezolizumab) within the body.Please speak with your healthcare team for more information about Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) to see if it may be a good option for you. If you have questions about treatment, trials, or biomarker testing, contact our LungMATCH team at support@go2.org or 1-800-298-2436. Read the full FDA announcement.

This is some text inside of a div block.

Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.